EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Biologics in congenital ichthyosis: are they effective?

Juliette Mazereeuw-Hautier iD, Céline Granier Tournier iD, Angela Hernandez-Martin, Sarah Milesi, Hélène Texier, Maëlla Severino-Freire, Nathalia Bellon, Christine Bodemer, Robert Gruber, Emmanuel Mahé iD, Fanny Morice Picard iD, Katariina Hannula-Jouppi und 17 weitere

British Journal of Dermatology · 24.01.2025 · 192 (2) · 327-334

DOI: 10.1093/bjd/ljae420 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Dermatology, online erschienen am 29.10.2024. Verfasst von Juliette Mazereeuw-Hautier und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Reference Centre for Rare Skin Diseases, Toulouse University Hospital, Paul Sabatier University, Toulouse, France. Hauptthemen laut MEDLINE: Biological Products, Ichthyosiform Erythroderma, Congenital, Netherton Syndrome, Dermatologic Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: ERN-Skin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Congenital ichthyoses comprise a heterogeneous group of genetic diseases that require lifelong treatment and have a major impact on patients’ quality of life. Conventional treatments reduce scaling and skin discomfort; however, they usually have little or no effect on erythema and pruritus. The identification of cytokine alterations in congenital ichthyoses has raised the possibility of repurposing currently available biologics. Several case reports have reported success with different biologics.

Objectives

To report the real-life effects of biologics on congenital ichthyoses.

Methods

This was a retrospective observational international multicentric study of patients with congenital ichthyoses treated with at least one biologic for a minimum of 3 months. The effect of the biologics was evaluated using an Investigator Global Assessment for change (IGA-C) scale. A comprehensive literature search was performed in parallel.

Results

Ninety-eight patients were included [mean (SD) age of 19.7 years, 50 female patients]. Patients with Netherton syndrome (NS) or congenital ichthyosiform erythroderma (CIE) represented the majority of patients (30% and 21%, respectively). Most patients (85%) had a severe or very severe form of congenital ichthyoses. The most frequently used biologics were inhibitors targeting interleukin (IL)-17, IL-12/IL-23 or the IL-4 receptor (IL-4R). The mean (SD) duration of treatment was 22.1 (20.1) months. There were 45 responders (46%), including 18 (18%) who were good responders; all had a subset of erythrodermic congenital ichthyoses and received one of the three main biologics. In patients with NS and CIE, IL-12/IL-23 and IL-4R inhibitors tended to be most effective. The literature review revealed a shorter mean (SD) duration of biologic treatment [11.5 (8.5) months] and higher percentage of responders (86%), suggesting reporter bias.

Conclusions

This series identified subsets of congenital ichthyoses that may respond to biologics and will help with the design of future clinical trials of biologics for congenital ichthyoses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsIchthyosiform Erythroderma, CongenitalNetherton SyndromeDermatologic AgentsHumansFemaleRetrospective StudiesMaleYoung AdultAdultTreatment OutcomeAdolescentChildChild, PreschoolQuality of LifeInfant

Substanzen

Biological ProductsDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Reference Centre for Rare Skin Diseases, Toulouse University Hospital, Paul Sabatier University, Toulouse, France.
  • Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.

ORCID-Profile: Juliette Mazereeuw-Hautier, Céline Granier Tournier, Emmanuel Mahé, Fanny Morice Picard, Sébastien Barbarot, Christine Chiaverini, Cristina Has

Förderung

  • ERN-Skin

Zitieren

APA

Mazereeuw-Hautier, J., Granier Tournier, C., Hernandez-Martin, A., Milesi, S., Texier, H., Severino-Freire, M., Bellon, N., Bodemer, C., Gruber, R., Mahé, E., Morice Picard, F., Hannula-Jouppi, K., Murase, J. E., Barbarot, S., Cohen-Barak, E., Torres-Pradilla, M., Bruckner, A., Levy, M., Koh, M. J. A., …, & Paller, A. S. (2025). Biologics in congenital ichthyosis: are they effective?. British Journal of Dermatology, 192(2), 327-334. https://doi.org/10.1093/bjd/ljae420

Vancouver

Mazereeuw-Hautier J, Granier Tournier C, Hernandez-Martin A, Milesi S, Texier H, Severino-Freire M, et al. Biologics in congenital ichthyosis: are they effective?. British Journal of Dermatology. 2025;192(2):327-334. doi:10.1093/bjd/ljae420

BibTeX
@article{MazereeuwHautier2025,
  author = {Mazereeuw-Hautier, Juliette and Granier Tournier, Céline and Hernandez-Martin, Angela and Milesi, Sarah and Texier, Hélène and Severino-Freire, Maëlla and Bellon, Nathalia and Bodemer, Christine and Gruber, Robert and Mahé, Emmanuel and Morice Picard, Fanny and Hannula-Jouppi, Katariina and Murase, Jenny E and Barbarot, Sébastien and Cohen-Barak, Eran and Torres-Pradilla, Maurico and Bruckner, Anna and Levy, Moise and Koh, Mark J A and Masson Regnault, Marie and Rossel, Vanya and Chiaverini, Christine and Arkin, Lisa M and Ott, Hagen and Has, Cristina and Süβmuth, Kira and Gostynski, Antoni and Shourick, Jason and Paller, Amy S},
  title = {Biologics in congenital ichthyosis: are they effective?},
  journal = {British Journal of Dermatology},
  year = {2025},
  volume = {192},
  number = {2},
  pages = {327--334},
  doi = {10.1093/bjd/ljae420}
}
Kostenlos starten →